全文获取类型
收费全文 | 1342787篇 |
免费 | 96991篇 |
国内免费 | 3216篇 |
专业分类
耳鼻咽喉 | 19809篇 |
儿科学 | 40387篇 |
妇产科学 | 38736篇 |
基础医学 | 188226篇 |
口腔科学 | 40009篇 |
临床医学 | 113751篇 |
内科学 | 263712篇 |
皮肤病学 | 30372篇 |
神经病学 | 106799篇 |
特种医学 | 54039篇 |
外国民族医学 | 437篇 |
外科学 | 209172篇 |
综合类 | 32108篇 |
现状与发展 | 8篇 |
一般理论 | 440篇 |
预防医学 | 92641篇 |
眼科学 | 31561篇 |
药学 | 101145篇 |
12篇 | |
中国医学 | 3451篇 |
肿瘤学 | 76179篇 |
出版年
2018年 | 12108篇 |
2016年 | 10886篇 |
2015年 | 12272篇 |
2014年 | 17207篇 |
2013年 | 25843篇 |
2012年 | 33804篇 |
2011年 | 35585篇 |
2010年 | 21261篇 |
2009年 | 20621篇 |
2008年 | 34060篇 |
2007年 | 37178篇 |
2006年 | 37689篇 |
2005年 | 36398篇 |
2004年 | 35430篇 |
2003年 | 34400篇 |
2002年 | 33852篇 |
2001年 | 63785篇 |
2000年 | 65462篇 |
1999年 | 55485篇 |
1998年 | 14722篇 |
1997年 | 13513篇 |
1996年 | 12981篇 |
1995年 | 12268篇 |
1994年 | 11500篇 |
1992年 | 42798篇 |
1991年 | 41340篇 |
1990年 | 40588篇 |
1989年 | 39580篇 |
1988年 | 36993篇 |
1987年 | 36436篇 |
1986年 | 34913篇 |
1985年 | 33115篇 |
1984年 | 24840篇 |
1983年 | 21063篇 |
1982年 | 12672篇 |
1981年 | 11572篇 |
1979年 | 23937篇 |
1978年 | 17077篇 |
1977年 | 14841篇 |
1976年 | 13391篇 |
1975年 | 15275篇 |
1974年 | 18089篇 |
1973年 | 17576篇 |
1972年 | 16815篇 |
1971年 | 15721篇 |
1970年 | 14919篇 |
1969年 | 14355篇 |
1968年 | 13463篇 |
1967年 | 12016篇 |
1966年 | 11261篇 |
排序方式: 共有10000条查询结果,搜索用时 578 毫秒
41.
42.
43.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
44.
45.
Wai Man Mandy Chan Yik Weng Yew Thiam Seng Colin Theng Choon Fong Liew Hazel H Oon 《Singapore medical journal》2020,61(4):194
INTRODUCTIONPsoriasis is a chronic inflammatory condition that affects the skin and joints, and is associated with cardiovascular risk factors, including metabolic syndrome (MetS). We aimed to assess the prevalence of MetS in patients with psoriasis and determine whether there was a correlation between psoriasis severity and MetS in a Singapore population.METHODSThis was a cross-sectional study of patients with psoriasis, aged 18–69 years, who attended a tertiary dermatology referral centre in Singapore from October 2007 to February 2009. Fasting glucose, lipids, blood pressure, Psoriasis Area and Severity Index, and body mass index were measured. MetS was diagnosed in the presence of three or more criteria of the modified National Cholesterol Education Program Adult Treatment Panel III.RESULTSAmong 338 patients with psoriasis, there were 238 (70.4%) men and 100 (29.6%) women, who were Chinese (n = 228; 67.5%), Malay (n = 52; 15.4%) and Indian (n = 58; 17.2%). The prevalence of MetS was 45.1%. MetS was 44% more prevalent in patients older than 50 years (p = 0.02). Malay patients with psoriasis were significantly more likely to have hypertriglyceridaemia, elevated fasting plasma glucose and abdominal obesity. There was no significant correlation between psoriasis severity and risk of MetS.CONCLUSIONThe prevalence of MetS in patients with psoriasis in Singapore was 45.1%, or nearly threefold higher than the Singapore general population. Patients with psoriasis should be screened yearly for MetS and any modifiable cardiovascular risk factors should be actively controlled. 相似文献
46.
47.
48.
目的研究和开发支持中医和现代生物医学本体和术语集的语义标注系统。方法以MedPortal本体库和中医临床术语集等为术语资源库,设计语义标注系统工作流程和功能框架,并开发Web应用系统。结果构建了一个基于Web的中医药文献语义标注系统,支持语料库管理与维护、术语词典管理、语义标注和语义检索等功能,既可以为基于机器学习的信息抽取算法研究提供训练集,又能实现语义层面的多来源数据集成与知识融合。结论该中医药文献语义标注系统设计方案已经过实际项目验证,可为其他同类系统研发提供参考。 相似文献
49.
50.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献